Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Telix Pharmaceuticals Announces FDA Approves Phase II Kidney Cancer Therapy Study

14 Sep 2021  |  08:37:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: FDA Approves Phase II Kidney Cancer Therapy Study

Telix Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) to undertake a clinical study of the Company's investigational kidney cancer therapy, TLX250 (177Lu-DOTAgirentuximab). The STARLITE 2 study is a single arm, investigator-led Phase II study in patients with advanced clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

Please click here for full details

See more ASX300 News Announcements